Nialamide
From Wikipedia, the free encyclopedia
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
N-benzyl-3-(N'-(pyridine-4-carbonyl)hydrazino)propanamide
|
|
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Legal status |
|
| Routes of administration |
Oral |
| Identifiers | |
| CAS Number | 51-12-7  |
| ATC code | N06AF02 |
| PubChem | CID 4472 |
| DrugBank | DB04820 |
| ChemSpider | 4317 |
| UNII | T2Q0RYM725 |
| KEGG | D07337 |
| Chemical data | |
| Formula | C16H18N4O2 |
| Molar mass | 298.34 g/mol |
|
|
|
|
| (verify) |
Nialamide (Niamid, Niamide, Nuredal, Surgex) is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class that was used as an antidepressant.[1] It was withdrawn by Pfizer several decades ago due to the risk of hepatotoxicity.[2][3]
See also[edit]
References[edit]
- ^ William Andrew Publishing (1 December 2006). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. pp. 2935–. ISBN 978-0-8155-1856-3.
- ^ Shayne C. Gad (26 April 2012). Safety Pharmacology in Pharmaceutical Development: Approval and Post Marketing Surveillance, Second Edition. CRC Press. pp. 138–. ISBN 978-1-4398-4567-7.
- ^ Edward Shorter (28 September 2008). Before Prozac : The Troubled History of Mood Disorders in Psychiatry: The Troubled History of Mood Disorders in Psychiatry. Oxford University Press. pp. 137–. ISBN 978-0-19-970933-5.
|
|
|
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
